Neoadjuvant chemotherapy for the management of ovarian cancer

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 16, Issue 4, 2002, Pages 585-596

  Schwartz, Peter E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytoreductive surgery; Interval debulking surgery; Neoadjuvant chemotherapy; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; PLATINUM DERIVATIVE;

ADJUVANT CHEMOTHERAPY; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; HUMAN; LAPAROTOMY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; ADJUVANT THERAPY; FEMALE; OVARY TUMOR; PATIENT SELECTION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PATIENT SELECTION;

EID: 0036674608     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2002.0304     Document Type: Article

References (43)

1. Greenlee RT, Hill-Harmon BH, Murray T et al. Cancer Statistics, 2001. Cancer Journal for Clinicians 2001; 51: 15-37.
2. Taylor KJW & Schwartz PE. Cancer screening in a high risk population: a clinical trial. Ultrasound in Medicine and Biology 2001; 27: 461-466.
3. Cannistra SA. Cancer of the ovary. New England Journal of Medicine 1993; 329: 1550-1559.
4. Tait L. The Pathology and Treatment of Disease of Ovaries, 4th edn, p 253. New York: William Wood & Co, 1983.
5. Lynch F. A clinical review of 110 cases of ovarian cancer. American Journal of Obstetrics and Gynecology 1936; 32: 753-772.
6. Pemberton FA. Carcinoma of the ovary. American Journal of Obstetrics and Gynecology 1941; 40: 751-760.
7. Munnell EW. The changing prognosis and treatment in cancer of the ovary. A report of 235 patients with primary ovarian carcinoma 1952-1961. American Journal of Obstetrics and Gynecology 1968; 100: 790-805.
8. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian cancer. Monographs of the National Cancer Institute 1975; 45: 101-104.
9. Schwartz PE. Surgical management of ovarian cancer. Archives of Surgery 1981; 116: 99-106.
10. Hoskins WJ, Bundy BN, Thigpen HJT & Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecologic Oncology 1992; 47: 156-166.
11. Vergote IB, DeWever I, Decloedt J et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Seminars in Oncology 2000; 27: 31-36.
12. Hunter RW, Alexander ND & Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? American Journal of Obstetrics and Gynecology 1992; 166: 504-511.
13. Kaye SB & van Houwelingen HC. What have we learnt from meta-analyses in ovarian cancer. Annals of Oncology 1993; (supplement 4): 79-82.
14. Allen DG, Heintz AP & Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. European Journal of Gynaecological Oncology 1995; 16: 349-356.
15. Ozols RF, Rubin SC, Thomas G & Robboy S. Epithelial ovarian cancer. In Hoskins WJ et al (eds) Principles and Practice of Gynecologic Oncology, 2nd edn, pp 919-986. Philadelphia: Lippincott-Raven Publishers, 1997.
16. Burns BC Jr, Rutledge FN, Smith JP et al. Management of ovarian cancer. Surgery, irradiation and chemotherapy. American Journal of Obstetrics and Gynecology 1967; 98: 374-386.
17. Fisher RI & Young RC. Advances in the staging and treatment of ovarian cancer. Cancer 1977; 39: 967-972.
18. DePalo GM, DeLena M, deRe F et al. Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary. Surgical Gynecology and Obstetrics 1975; 141: 899-902.
19. Young RD, Cannellos GP, Chabner BA et al. Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. Gynecologic Oncology 1974; 2: 489-497.
20. Wharton JT, Rutledge R, Smith JP et al. Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer. American Journal of Obstetrics and Gynecology 1979; 133: 833-841.
21. Vogl S, Pagano M, Kaplan BH et al. Cisplatin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens. Cancer 1983; 51: 2024-2030.
22. Bruckner HW, Cohen CJ, Goldberg JD et al. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer. American Journal of Obstetrics and Gynecology 1983; 145: 653-658.
23. Edmonson JH, McCormack GW, Fleming TR et al. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas. Cancer Treatment Reports 1985; 69: 1243-1248.
24. Greco FA, Julian CG, Richardson RL et al. Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation. Obstetrics and Gynecology 1981; 58: 199-205.
25. Schwartz PE, Chambers JT, Kohorn EI et al. Tamoxifen in combination with cytotoxic chemotherapy in advanced ovarian cancer: a prospective randomized trial. Cancer 1989; 63: 1074-1078.
26. Eisenkop SM, Nalick RH & Teng NN. Modified posterior exenteration for ovarian cancer. Obstetrics and Gynecology 1991; 78: 879-885.
27. Adelson MD. Cytoreduction of diaphragmatic metastases using the Cavitron ultrasound surgical aspirator. Gynecologic Oncology 1991; 41: 220-222.
28. Farghaly SA. Surgical techniques for cytoreduction in advanced ovarian malignancy. American Journal of Obstetrics and Gynecology 1993; 168: 736.
29. Neijt JP, ten Bokkel Huinink WW, van der Burg ME et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. Journal of Clinical Oncology 1987; 5: 1157-1168.
30. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. New England Journal of Medicine 1995; 332: 629-634.
31. Chambers JT, Chambers SK, Voynick IM & Schwartz PE. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecologic Oncology 1990; 37: 327-331.
32. Schwartz PE, Chambers JT & Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology 1994; 55: 33-37.
33. Schwartz PE, Rutherford TJ, Chambers JT et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecologic Oncology 1999; 72: 93-99.
34. Surwit E, Childers J, Atlas I et al. Neoadjuvant chemotherapy for advanced ovarian cancer. International Journal of Gynecologic Cancer 1996; 6: 356-366.
35. Ansquer Y, Leblanc E, Clough K et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer 2001; 81: 2329-2334.
36. Vergote I, DeWever I, Tjalma W et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecologic Oncology 1998; 71: 431-436.
37. Onnis A, Marchetti M, Radovan P & Castellan L. Neoadjuvant chemotherapy in advanced ovarian cancer. European Journal of Gynaecological Oncology 1996; 17: 393-396.
38. Nelson BE, Rosenfield AT & Schwartz PE. Preoperative abdominopelvic computed tomography prediction of optimal cytoreduction in epithelial ovarian carcinoma. Journal of Clinical Oncology 1993; 11: 166-172.
39. Meyer JI, Kennedy AW, Friedman R et al. Ovarian carcinoma: value of CT in predicting success of debulking surgery. American Journal of Roentgenology 1995; 165: 875-878.
40. Chi DS, Venkatraman ES, Masson V et al. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian cancer. Gynecologic Oncology 2000; 77: 227-231.
41. Gemer O, Segal S & Kopmar A. Preoperative CA-125 level as a predictor of non-optimal cytoreduction of advanced epithelial ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica 2001; 80: 583-585.
42. Eisenkop SM, Friedman RL & Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology 1998; 69: 102-108.
43. 32P). Annals of Oncology 1995; 6: 887-894.